| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | CARA | Common Stock, par value $0.001 per share | 7.4M | Oct 20, 2021 | See Notes | F1, F2, F3 |
| Id | Content |
|---|---|
| F1 | In addition to Vifor (International) Ltd., an entity formed under the laws of Switzerland ("Vifor (International)"), this Form 3 is being filed by Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland ("VFMCRP"), and Vifor Pharma Ltd., an entity formed under the laws of Switzerland ("Vifor Pharma" and together with Vifor and VFMCRP, the "Reporting Persons"). The business addresses for each of the Reporting Persons are listed above. Each of the Reporting Persons may be deemed to have a pecuniary interest in securities reported by it on this Form 3 (the "Subject Securities"). |
| F2 | VFMCRP's beneficial ownership of the common stock referred to herein is being reported solely because VFMCRP may be deemed to beneficially own 6,221,943 shares of Common Stock of Cara Therapeutics, Inc. as a result of its right to acquire such shares upon exercise of an option granted to it by Vifor (International). Vifor Pharma's beneficial ownership of the common stock referred to herein is being reported solely because Vifor Pharma may be deemed to beneficially own 7,396,770 shares of Common Stock of Cara Therapeutics, Inc. as a result of its indirect ownership of 100% of the equity interests of Vifor (International) and 55% of the equity interests of VFMCRP. |
| F3 | Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein. |